Drug intelligence / Profile preview

NCX 125

Development stage: Preclinical
Lead developer: NicOx Research Institute
Modality: Small Molecules
Administration: Ophthalmic

Overview

NCX 125 is a nitric oxide-releasing prostaglandin analog designed to lower intraocular pressure, primarily studied for potential use in glaucoma and ocular hypertension. Its dual mechanism of action involves the prostaglandin analogic effect, which increases uveoscleral outflow, and the nitric oxide donation, which enhances trabecular meshwork outflow, resulting in potent ocular hypotensive effects demonstrated in animal models (rabbits, dogs, primates)[1][4][7][11].

Targets

PTGFR (Prostaglandin F2 alpha receptor)sGC (Soluble Guanylyl Cyclase)

Beyond the preview

Go deeper on NCX 125.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NCX 125.

Explore the full profile